Scholarlink

Purpose of Review <p>Summarize the current evidence and ongoing progress in immunotherapy response predictors for triple negative breast cancer (TNBC).</p> Recent Findings <p>The incorporation of immunotherapy in the treatment of TNBC, in both the early and the advanced/metastatic settings, has changed the landscape of TNBC management. However, not all patients with TNBC benefit from the addition of immunotherapy, and given the potentially serious immune related adverse effects, there is an urgent need to identify and validate biomarkers that can predict which patients are most likely to respond to and benefit from immunotherapy.</p> Summary <p>The treatment paradigm for TNBC is evolving rapidly. Immunotherapy in conjunction with chemotherapy, antibody-drug conjugates, or other novel therapeutics is emerging as a key component of TNBC treatment. This review focuses on the recent advances in immunotherapy response biomarkers at various stages of investigation and development. We also provide some insight is into how these biomarkers may be applied for patient selection and personalized management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of Immunotherapy Response in Triple Negative Breast Cancer

  • 期刊论文

  • 发表日期：

    2025年3月7日

查看全文
  • Yiduo Hu,
  • Rachel Yoder,
  • Priyanka Sharma

摘要

Purpose of Review

Summarize the current evidence and ongoing progress in immunotherapy response predictors for triple negative breast cancer (TNBC).

Recent Findings

The incorporation of immunotherapy in the treatment of TNBC, in both the early and the advanced/metastatic settings, has changed the landscape of TNBC management. However, not all patients with TNBC benefit from the addition of immunotherapy, and given the potentially serious immune related adverse effects, there is an urgent need to identify and validate biomarkers that can predict which patients are most likely to respond to and benefit from immunotherapy.

Summary

The treatment paradigm for TNBC is evolving rapidly. Immunotherapy in conjunction with chemotherapy, antibody-drug conjugates, or other novel therapeutics is emerging as a key component of TNBC treatment. This review focuses on the recent advances in immunotherapy response biomarkers at various stages of investigation and development. We also provide some insight is into how these biomarkers may be applied for patient selection and personalized management.